This article is more than 5 years old. Information may no longer be current.

VIDEO: Study provides ‘eagerly awaited’ data on PARP inhibitors

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — The PARP inhibitor talazoparib demonstrated activity in patients with germline BRCA mutations, according to results presented at the ASCO Annual Meeting.

Jame Abraham, MD, director of the breast oncology program at Cleveland Clinic, discusses the phase 2 study, which was conducted in women with breast cancer who had received prior therapy.

“Talazoparib (BMN 673) is probably one of the most active PARP inhibitors based on preclinical studies,” Abraham said. “An ongoing study looking at talazoparib vs. treatment of physician’s choice will give us more mature data to see how this is going to fit into our clinical practice.”